Immunology of Diabetes

Marta Vives-Pi

The multidisciplinary Immunology of Diabetes Group at the IGTP is part of the Immunology Section of the Germans Trias i Pujol University Hospital (HUGTiP). It is made up of researchers, endocrinologists, pediatricians and technicians; the group works to understand more about the causes of type 1 diabetes. The research of the group is focused on translational research: Immunotherapies for the prevention and treatment of Type 1 diabetes, Pathogenic mechanisms of autoimmunity and Pediatric type 1 diabetes: tolerance, spontaneous remission and biomarkers. Their wish is to contribute to therapeutic intervention in type 1 diabetes and other autoimmune diseases. The principal investigator, Marta Vives-Pi (MSc and PhD), has been working in the field of autoimmune diseases since 1988. Since 1996 she has been the leader of several research projects, stressing the development of experimental immunotherapies. In 2000 she started the specific pathogen free Unit (SPF) at the IGTP for the study of experimental models of type 1 diabetes. Moreover, M. Vives-Pi is co-founder and Scientific Director of Ahead Therapeutics S.L. a spin-off to transfer the immunotherapy generated by the group to the clinical arena and convert know-how into treatments for autoimmune diseases such as type 1 diabetes or multiple sclerosis.

Group Members

Marta Vives-Pi, (ELIMINAR)mvives(ELIMINAR)@igtp.cat, Group Leader and PI
Silvia Rodríguez Fernández,srodriguez(ELIMINAR)@igtp.cat, Predoctoral Investigator
David Perna Barrul, dperna(ELIMINAR)@igtp.cat, Predoctoral Investigator
Rosa M Ampudia, rampudia(ELIMINAR)@igtp.cat, Research Technician
Adrián Villalba, avillalba(ELIMINAR)@igtp.cat, Predoctoral Investigator

Publications

See Publications Marta Vives-Pi

Grup Vives 2016.02.08

Research lines

Immunotherapies for the prevention and treatment of type 1 diabetes

The line of research aims to stop the autoimmune response using innovative therapies to re-establish the cellular tolerance of the insulin-producing cells.

This line of research is funded by Instituto de Salud Carlos III and Fundació La Marató de TV3.

Pathogenic mechanisms of autoimmunity

This line of research aims to identify the mechanisms of the specific immune responsible for destruction of insulin-producing beta cells, with special atention to prenatal environmental factors.

Pediatric type 1 diabetes: tolerance, spontaneous remission and biomarkers

The aim of this line is to explore mechanisms of tolerance restablishment in children at the onset of the disease, and to define new biomarkers of remission.

This line of research is funded by DiabetesCERO.

Projects

A new dawn for type 1 diabetes: Combining a nanotherapy to halt autoimmunity with beta-cell regeneration

Code: 201632_10
Principlal Investigator Marta Vives-Pi                                                                                              
Start Date: 01/03/2017
End Date: 29/02/2020

TV3_la_marato

Efecto terapéutico de nano-liposomas en diabetes tipo 1. Determinaciones preclínicas

Code: PI15/00198
Principal Investigator: Marta Vives-Pi                                                                                                
Start Date: 01/01/2016
End Date: 31/12/2018

Terapia contra la autoinmunidad para la prevención y la curación de la diabetes tipo 1. Nanopartículas tipo liposoma que re-educan el sistema inmunológico para permitir la regeneración de las células beta

Code: Cer001
Principle Investigator: Marta Vives-Pi                                                                                              
Start Date: 01/06/2017
End Date: 31/05/2019

DiabetisCERO

CIBERDEM IGTP Project

Code: CB15/00071
Principle Investigator: Didac Mauricio                                                                                            
Start Date: 2015

CIBERDEM
 

Spin-off  Company

More information

Contact

Marta Vives-Pi, PhD, Principal Investigator

(+34) 93 497 86 66

mvives(ELIMINAR)@igtp.cat